in addition to distributing supplements containing ED ingredients, MS Bionic was in violation of an extensive list of supplement GMP regulations. Meanwhile Absonutrix makes claims for its herbals and botanicals including "aids in the inhibition of colon cancer cell growth and survival."
MS Bionic Inc.'s recall in 2016 after FDA found erectile dysfunction drugs in products the California firm marketed as dietary supplements was just the tip of its problems, according to the agency's latest warning letters submitted to supplement firms.
The letters FDA posted Aug. 1 also include the Office of Regulatory Affairs' warning to Absonutrix LLC about making drug...
Create an account to read this article
Already a subscriber?
Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.
White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.
The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful
FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.
Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.
The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful
FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.
